{'52WeekChange': -0.7263479,
 'SandP52WeekChange': None,
 'address1': 'Chemin des Aulx, 12',
 'address2': 'Plan-les-Ouates',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.79,
 'askSize': 2900,
 'averageDailyVolume10Day': 870150,
 'averageVolume': 1141888,
 'averageVolume10days': 870150,
 'beta': 1.103965,
 'beta3Year': None,
 'bid': 2.72,
 'bidSize': 1800,
 'bookValue': 0.834,
 'category': None,
 'circulatingSupply': None,
 'city': 'Geneva',
 'companyOfficers': [],
 'country': 'Switzerland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.8,
 'dayLow': 2.65,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.897,
 'enterpriseToRevenue': 6139.804,
 'enterpriseValue': 92097056,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.415,
 'fiftyTwoWeekHigh': 10.35,
 'fiftyTwoWeekLow': 1.63,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 28367681,
 'forwardEps': -1.3,
 'forwardPE': -2.1384616,
 'fromCurrency': None,
 'fullTimeEmployees': 53,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0608,
 'heldPercentInstitutions': 0.52071,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/obseva.com',
 'longBusinessSummary': 'ObsEva SA, a clinical-stage biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of novel therapeutics for women '
                        'suffering from reproductive health and pregnancy. The '
                        'company is developing Linzagolix, an oral '
                        'gonadotropin-releasing hormone receptor antagonist '
                        'for the treatment of pain associated with '
                        'endometriosis and heavy menstrual bleeding associated '
                        'with uterine fibroids in pre-menopausal women. It '
                        'also is developing OBE022, an oral and selective '
                        'prostaglandin F2a, or PGF2a receptor antagonist, as a '
                        'once daily treatment for preterm labor in weeks 24 to '
                        '34 of gestational age; and Nolasiban, an oral '
                        'oxytocin receptor antagonist to enhance clinical '
                        'pregnancy and live birth rates in women undergoing in '
                        'vitro fertilization. The company was founded in 2012 '
                        'and is headquartered in Geneva, Switzerland.',
 'longName': 'ObsEva SA',
 'market': 'us_market',
 'marketCap': 130814008,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_245335894',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -104974000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.65,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '41 22 552 38 40',
 'previousClose': 2.69,
 'priceHint': 4,
 'priceToBook': 3.3333333,
 'priceToSalesTrailing12Months': 8720.934,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.8,
 'regularMarketDayLow': 2.65,
 'regularMarketOpen': 2.65,
 'regularMarketPreviousClose': 2.69,
 'regularMarketPrice': 2.65,
 'regularMarketVolume': 889008,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44592100,
 'sharesPercentSharesOut': 0.0146,
 'sharesShort': 685835,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 643979,
 'shortName': 'ObsEva SA',
 'shortPercentOfFloat': 0.0201,
 'shortRatio': 0.85,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'OBSV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.375,
 'twoHundredDayAverage': 3.4649713,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2316098a-c803-32fb-b2c4-3e320534661f',
 'volume': 889008,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.obseva.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '1228'}